BioCryst Pharmaceuticals develops and sells medicines for hereditary angioedema and other rare diseases. It last closed at $7.22 on Nov 20, down 1.37% on the day. The next earnings report for BCRX is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, BCRX reported EPS of $0.14 on revenue of $180.3M, with revenue up 13.1% from a year ago. Over its last 8 reports the stock moved an average of 7.3% the session after earnings. Over the last 12 months BCRX insiders bought $0 of stock on the open market and sold $4.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is BCRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BCRX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BCRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BCRX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 8% below its 20 day and 12% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $7.11, and the nearest resistance the Pivot at $7.25.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 4.4%/day
Key levels
$11.2252 week high+55.4%
$8.87100 day average+22.9%
$8.82200 day average+22.2%
$8.0850 day average+11.9%
$7.8320 day average+8.4%
$7.78Swing high (Nov 12)+7.8%
$7.36Pivot R1+1.9%
$7.25Pivot+0.4%
$7.22Last close
$7.11Pivot S1−1.5%
$6.2352 week low−13.7%
Indicators
RSI (14)
34.75
Weak, oversold below 30
Neutral
MACD
-0.25
Below its signal line
Bearish
Stochastic
4.3
Near the bottom of its range
Oversold
ADX (14)
14.9
No clear trend
Williams %R
-95.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-108.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−6.1%
Change over 10 sessions
Bearish
ATR (14)
$0.32
Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 12.2%/day
Key levels
$11.2252 week high+55.4%
$8.87100 day average+22.9%
$8.82200 day average+22.2%
$8.0850 day average+11.9%
$7.8320 day average+8.4%
$7.78Swing high (Nov 12)+7.8%
$7.36Pivot R1+1.9%
$7.25Pivot+0.4%
$7.22Last close
$7.11Pivot S1−1.5%
$6.2352 week low−13.7%
Indicators
RSI (14)
39.74
Weak, oversold below 30
Neutral
MACD
-0.34
Below its signal line
Bearish
Stochastic
6.3
Near the bottom of its range
Oversold
ADX (14)
15.4
No clear trend
Williams %R
-97.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-125.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.1%
Change over 10 sessions
Bearish
ATR (14)
$0.88
Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BCRX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow BCRX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BCRXHow many large options trades hit BCRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BCRX in the last 90 days.
From SEC Form 4 filings by BCRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCRX is in one of them and how their past BCRX trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Biocryst Pharmaceuticals
BioCryst Pharmaceuticals is a biotechnology company based in Durham, North Carolina. It develops and sells medicines for hereditary angioedema and other rare diseases. Its main product, ORLADEYO, is an oral medicine taken once daily to prevent attacks of hereditary angioedema, and it is approved in the United States and several other markets. The company also has RAPIVAB, an intravenous treatment for influenza, approved in several countries. Its customers include patients with these conditions, along with the healthcare providers and insurers who support their care.